Loading quotes...

Forecast

The analysts' average price target is €25.93 (+109.96%). The median is €25.93 (+109.96%).

Buy
  13
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • MediWound: VALUE study for EscharEx as decisive near-term catalyst

    MediWound presented its bromelain platform at the H.C. Wainwright conference, highlighting NexoBrid revenue potential and the upcoming VALUE phase III study for EscharEx as key drivers. The VALUE study (216 patients) includes an interim analysis at ~65% recruitment; various sample-size adjustments are possible, and topline data are expected about three months after the interim analysis. The company is expanding production capacity, expects European approval in mid‑2027, and points to commercial progress with NexoBrid as well as a BARDA-linked partnership with Vericel. » More on de.investing.com


  • MediWound calls extraordinary general meeting for Feb. 19

    MediWound has called an extraordinary general meeting for Feb. 19, 2026, and on Jan. 15, 2026 filed the related notice and a proxy statement with the SEC. Registered shareholders will receive voting materials and a proxy card. The filings give meeting details but do not disclose specific agenda items; the documents refer to existing registration statements on Forms S-8 and F-3. » More on de.investing.com


  • MediWound: study shows NexoBrid removes over 90% of traumatic tattoos

    A prospective study at Sheba Medical Center found that MediWound’s enzymatic preparation NexoBrid reduced the pigmented wound surface by an average of 92.5% in 15 patients (96% for abrasion injuries, 84% for blast injuries). The treatment was administered at the bedside under sedation within 24 hours and showed no treatment-related adverse events in early follow-up. MediWound recently raised around $30 million via a direct offering, received approval in Australia and is planning production and capacity expansions; one analyst raised the price target. » More on de.investing.com


  • MediWound raises $30 million through registered direct placement

    MediWound sold 1,734,105 ordinary shares at $17.30 per share in a registered direct placement, raising about $30 million. The transaction was led by a U.S. investment fund and other healthcare-focused investors; H.C. Wainwright & Co. served as sole placement agent. Net proceeds are intended to fund precommercial activities for EscharEx, expand manufacturing capacity and general corporate purposes. The company also reported TGA approval of NexoBrid in Australia and new study data on the importance of wound bed preparation. » More on de.investing.com


  • MediWound presents growth plan and cites supply bottlenecks for NexoBrid

    MediWound presented its growth strategy at the H.C. Wainwright conference, focusing on the phase-3 study of EscharEx and expansion of production capacity. The company reported supply chain problems with NexoBrid and plans a new manufacturing site in the US as well as an additional facility in Europe to address the shortages. Partnerships with BARDA and the DOD, cash of $33 million and a potential $30 million from warrants support the commercialization plans; a BARDA tender is expected in Q4 2025. » More on de.investing.com

Financials

In the last quarter, MediWound had revenue of €3.15M and net profit of -€5.29M
(EUR) September 2026
YoY
Revenue 3.15M 31.81%
Gross profit 897.86K 17.60%
Net profit -5.29M 133.89%
EBITDA -7.2M 287.68%

Fundamentals

Metric Value
Market capitalization
€159.14M
Number of shares
12.91M
52-week high/low
€20.10 - €10.73
Dividends No
Beta
0.14
P/E ratio
-7.45
PEG ratio
0.94
P/B ratio
5.53
P/S ratio
17.48

Company profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Name
MediWound
CEO
Ofer Gonen
Headquarters Yavne, hm
Israel
Website
Sector
Consumer Staples
Industry
Personal Care Products
IPO
03/20/2014
Employees 121

Ticker symbols

Exchange Symbol
NASDAQ
MDWD
Frankfurt
M8W.F
🍪

Parqet  uses cookies. Learn more